Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487

USA - English

News provided by

Oct 09, 2023, 11:49 ET

HNSA-5487 is a next-generation IgG-cleaving enzyme and the lead candidate in the NiceR development program

LUND, Sweden, Oct. 9, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced high-level results from NICE-01, the first-in-human trial for HNSA-5487. Results showed the molecule was safe and well tolerated. Fast and complete depletion of immunoglobulin G (IgG) antibodies was observed at increasing doses in all subjects. Pharmacokinetics (PK) was in line with expectations and pharmacodynamics (PD) (efficacy on IgG cleavage) showed a fast and complete cleavage of IgG to F(ab')₂- and Fc-fragments with increasing doses.

NICE-01 is a double blind, randomized, placebo-controlled trial evaluating safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of HNSA-5487 administered as a single intravenous (IV) infusion. The trial included a total of 36 healthy male and female adult participants.

HNSA-5487 is the company's lead candidate in the Novel Immunoglobulin Cleaving Enzymes for Repeat Dosing (NiceR) program. The NiceR program aims to develop next-generation enzymes with lower immunogenicity that would potentially allow for repeat dosing in a range of indications including IgG-driven autoimmune diseases where patients experience flares, transplantation where repeat dosing would be beneficial, gene therapy and oncology.

Søren Tulstrup, President and CEO, Hansa Biopharma said, "This is encouraging data as we continue to explore the potential for HNSA-5487 and better understand how this powerful, new enzyme could benefit patients and clinicians. An enzyme with lower immunogenicity would potentially enable repeat dosing, allowing a prolonged effect by flexibly extending the IgG-free window depending on the number of repeated infusions. This could enable innovative treatment approaches in a broad range of indications, and benefit patients with diseases where a prolonged IgG-free window is needed".

Analysis of additional exploratory endpoints on IgG recovery and immunogenicity is now being conducted, with follow up on all subjects for 12 months. This analysis will serve as key input in determining the further clinical development program, including selection of indications.

For further information, please contact:

Klaus Sindahl, VP Head of Investor Relations
M: +46 (0) 709–298 269
E: [email protected]

Stephanie Kenney, VP Global Corporate Affairs
M: +1 (484) 319 2802
E: [email protected]

The following files are available for download:

https://mb.cision.com/Main/1219/3850341/2347253.pdf

20231009-HNSA-5487 FIH -FINAL_en

SOURCE Hansa Biopharma AB